Indegene Limited has informed the Exchange that Board of Directors at its meeting held on April 28, 2025, recommended Final Dividend of 2 per equity share.
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Smallcap 250 and 1.5 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indegene's Board met on April 28, 2025 and approved audited consolidated and standalone results for the quarter and year ended March 31, 2025 with an unmodified auditor opinion. Consolidated FY25 revenue from operations grew to Rs. 28,393 million (from Rs. 25,896 million in FY24), while net profit rose to Rs. 4,067 million (from Rs. 3,367 million). Basic EPS for FY25 was Rs. 17.15 versus Rs. 15.19 the prior year. The Board recommended a final dividend of Rs. 2 per equity share (face value Rs. 2), which would result in a cash outflow of about Rs. 480 million, subject to shareholder approval at the upcoming AGM. The company also approved allotments under its RSU Scheme 2020. This is Indegene's first full reporting year since its May 2024 IPO.
The Rs. 2 final dividend is modest relative to the Rs. 452 IPO price (under 0.5% yield at issue), so the cash impact on shareholders is small but signals confidence in profitability. Strong FY25 revenue and profit growth of roughly 10% and 21% respectively, along with a clean audit, should be viewed positively by investors.